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Background: Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells appears to be a promising
immunotherapeutic strategy. CAR combines the specificity of antibody and cytotoxicity of cytotoxic T lymphocytes,
enhancing T cells’ ability to specifically target antigens and to effectively kill cancer cells. Recent efforts have been
made to integrate the costimulatory signals in the CAR to improve the antitumor efficacy. Epidermal growth factor
receptor variant III (EGFRvIII) is an attractive therapeutic target as it frequently expresses in glioma and many other
types of cancers. Our current study aimed to investigate the specific and efficient antitumor effect of T cells
modified with CAR containing inducible costimulator (ICOS) signaling domain.
Methods: A second generation of EGFRvIII/CAR was generated and it contained the EGFRvIII single chain variable
fragment, ICOS signaling domain and CD3ζ chain. Lentiviral EGFRvIII/CAR was prepared and human CD3+ T cells
were infected by lentivirus encoding EGFRvIII/CAR. The expression of EGFRvIII/CAR on CD3+ T cells was confirmed
by flow cytometry and Western blot. The functions of EGFRvIII/CAR+ T cells were evaluated using in vitro and
in vivo methods including cytotoxicity assay, cytokine release assay and xenograft tumor mouse model.
Results: Chimeric EGFRvIIIscFv-ICOS-CD3ζ (EGFRvIII/CAR) was constructed and lentiviral EGFRvIII/CAR were made to
titer of 106 TU/ml. The transduction efficiency of lentiviral EGFRvIII/CAR on T cells reached around 70% and
expression of EGFRvIII/CAR protein was verified by immunoblotting as a band of about 57 kDa. Four hour 51Cr
release assays demonstrated specific and efficient cytotoxicity of EGFRvIII/CAR+ T cells against EGFRvIII expressing
U87 cells. A robust increase in the IFN-γ secretion was detected in the co-culture supernatant of the EGFRvIII/CAR+
T cells and the EGFRvIII expressing U87 cells. Intravenous and intratumor injection of EGFRvIII/CAR+ T cells inhibited
the in vivo growth of the EGFRvIII expressing glioma cells.
Conclusions: Our study demonstrates that the EGFRvIII/CAR-modified T cells can destroy glioma cells efficiently in
an EGFRvIII specific manner and release IFN-γ in an antigen dependent manner. The specific recognition and
effective killing activity of the EGFRvIII-directed T cells with ICOS signaling domain lays a foundation for us to
employ such approach in future cancer treatment.
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Adoptive immunotherapy (AIT) has received much at-
tention as a form of cancer treatment in the past de-
cades. The adoptive transfer of the ex vivo cultured
tumor-infiltrating lymphocytes or lymphokine-activated
killer cells has been shown to mediate tumor regression
in certain type of cancers [1]. However, AIT has only
been used as adjuvant therapy in clinical practice, in-
stead of the first-line treatment, due to some limitations.
With advances in genetic engineering, immunotherapy
using genetically modified antigen specific T cells, has
become more attractive in the treatment of human ma-
lignancies. Chimeric antigen receptor (CAR), consisting
of a single chain variable fragment (scFv) of a tumor
antigen specific antibody and the signaling domains of T
cell receptor (TCR), is one of the strategies to genetically
modify T cells [2]. This strategy combines the antigen
specificity of antibodies and the cytotoxicity of cytotoxic
T lymphocytes (CTLs). CAR bypasses many of the mecha-
nisms through which tumor cells escape immunorecog-
nition, e.g., down-regulation of MHC and costimulatory
molecules, induction of suppressive cytokine and regu-
latory T cells, etc. Recent studies have generated some
encouraging preclinical and clinical data regarding the
CAR-mediated adoptive immunotherapy in a variety of
cancers including chronic lymphocytic leukemia, neuro-
blastoma and melanoma [3-5].
According to two-signal model of T cell activation [6],
complete T cell activation and the prevention of activa-
tion induced cell death require costimulatory signal like
CD28-B7 in addition to TCR/CD3 complex. The new
generation of CAR with the addition of costimulatory
molecules greatly strengthens its antitumor effects in
vitro and in vivo. Many reports showed that the en-
hanced antitumor activity is due to the activation, pro-
liferation and survival of the CAR T cells containing
costimulatory molecules [7]. To date, the most com-
monly used costimulatory molecule in CAR is CD28,
one of the best-characterized costimulatory molecules.
CD28 costimulation is essential for IL-2 production,
proliferation and survival of T cells, but thought to be
less important in memory and effector T cell responses
[8]. Inducible costimulator (ICOS), a B7 receptor family
member similar to CD28 in structure, is expressed on
activated T cells. Some studies have demonstrated high
cytotoxicity and more favorable Th1/Th2 cytokine pro-
duction due to costimulation by ICOS [9].
Both optimal design of the CAR architecture and care-
ful choice of the tumor associated antigen are important
prerequisite for attaining significant response in the
CAR-mediated immunotherapy. Epidermal growth factor
receptor variant III (EGFRvIII) is an oncogenic variant
frequently expressed in glioma and many other types of
cancers [10]. EGFRvIII is made of an in-frame deletionof exons 2–7 of EGFR, resulting in a truncated ex-
tracellular ligand binding domain and a constitutively
activated protein in a ligand-independent manner. The
expression of EGFRvIII is associated with survival, inva-
sion, angiogenesis and resistance to radiation and che-
motherapy in cancers, making it an attractive target
for cancer immunotherapy [11]. Currently, targeting of
EGFRvIII using strategies such as immunotoxin, vacci-
nation, and/or small molecular inhibitor are actively car-
ried out in both preclinical studies and clinical trials in
many laboratories [12,13].
In this study, a second generation CAR, namely,
EGFRvIII scFv-ICOS-CD3 ζ (hereafter named as
EGFRvIII/CAR), was constructed based on our previ-
ously generated EGFRvIII specific recombinant antibody
[14]. Lentivirus–mediated T cell transduction was used to
modify human T cells. The genetically engineered T cells
demonstrate a specific and efficient cytotoxicity against
EGFRvIII expressing glioma in vitro and in vivo.
Methods
Construction of chimeric antigen receptor and generation
of EGFRvIII expressing U87cell line
Chimeric EGFRvIII/CAR is composed of EGFRvIII scFv
and ICOS-CD3ζ expression cassette. The EGFRvIII scFv
was derived from a high-affinity EGFRvIII monoclo-
nal antibody described previously with the order of a
light chain -(GGGS)3- a heavy chain (726 bp) [14]. ICOS-
CD3ζ expression cassette consisting a hinge and a trans-
membrane (TM) region was designed and synthesized
by Anji Biotechnology Company, as shown in Figure 1A.
The two fragments of EGFRvIII scFv and ICOS-CD3ζ
were connected in-frame by overlap PCR. The generated
EGFRvIII/CAR was verified by DNA sequencing and
cloned into EcoRI and BamHI sites of lentiviral vector
pCDH-EF1-T2A-puro (System Biosciences, CA). The new
vector was named pCDH-EGFRvIII/CAR. The sequences
of all PCR primers are provided on request.
Human glioma cell line U87 was bought from Chinese
Academy of Science in Shanghai and maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen,
CA) supplemented with 10% FBS, 50 U/ml penicillin and
50 μg/ml streptomycin. The EGFRvIII expressing U87
cell line was generated by selecting stably transfected
pcDNA3.1-EGFRvIII of U87 cells and cultured in DMEM
containing 10% FBS and 400 μg ⁄ml G418.
Preparation of lentiviral EGFRvIII/CAR
Lentiviral EGFRvIII/CAR was generated by calcium phos-
phate cotransfections of HEK293T cells with three plas-
mids (pVSV-G, pCMV-dR8.9 and pCDH-EGFRvIII/CAR)
as described previously [15]. Harvested supernatants of
transfected cells containing lentiviral particles were fil-
tered and concentrated by ultracentrifugation. The titers







































Figure 1 Evaluation of EGFRvIII/CAR expression on CD3+ T cells. (A) Schematic representation of EGFRvIII/CAR. It consists of EGFRvIII scFv, the
hinge and transmenbrane (TM) region of human CD8α, ICOS signaling domain, and human CD3ζ chain. IgG κ chain was used as signal peptide
(SP). (B) Surface expression of EGFRvIII/CAR on CD3+ T cells. Left, isotype control; Middle, anti-human CD3-FITC and anti-human CD8-PE staining
(BD Biosciences); Right, anti-mouse F(ab)2-FITC (eBiocience) and anti-human CD8-PE staining. (C) Immunoblot analysis of EGFRvIII/CAR expression.
Lysates of untransduced T cells (lanes 1) and EGFRvIII/CAR transduced T cells (lane 2) were separated by SDS-PAGE under reducing condition.
Goat anti-human CD3ζ antibody was used to detect the endogenous and chimeric CD3ζ expression.
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Kit (Cell BioLabs).
Transduction of activated CD3+ T cells with lentiviral
EGFRvIII/CAR
The CD3+ T cells were activated and transduced with
lentiviral EGFRvIII/CAR as described previously [16].
Briefly, peripheral blood mononuclear cells (PBMCs) were
isolated by Lymphoprep (Solarbio) gradient centrifugation.
After washing and equilibrating with MACS buffer, T
cells were isolated using CD3+ magnetic beads (Miltenyi
Biotec). CD3+ T cells at [5×105 cells/ml] were then acti-
vated with CD3/CD28 Dynabeads (Life Technologies) for
three days. The activated CD3+ T cells were harvested and
hereafter expanded in the presence of IL-2 (30 units/ml)
for 7 days. Then, the activated CD3+ T cells were infected
with lentiviral EGFRvIII/CAR at MOI of 5 in the presence
of IL-2 (30 units/ml). After 96h, cells were collected for
further analysis. All blood samples were obtained from
healthy volunteers under an institutional review board-
approved protocol.
Evaluation of EGFRvIII/CAR expression on CD3+ T cells
Flow cytometric analysis was used to detect surface ex-
pression of EGFRvIII/CAR on CD3+ T cells. Cells were
washed once with PBS containing 2% FBS/0.1% sodium
azide and then incubated with the corresponding fluor-
escent antibody (2 μl/3×105 cells) for 30 min at 4°C in
the dark. After that, the cells were washed again andfixed in 0.5% paraformaldehyde/FACS buffer before
analysis. Flow cytometric analyses were performed on
BD FACSAria II with CellQuest Pro software. In all
cases, >10,000 events was analyzed with antibody isotype
control.
Western blot was done to verify the expression of
EGFRvIII/CAR protein. T cells (3×106) were lysed in
100 μl lysis buffer. After centrifugation, cell lysates were
denatured under reducing condition and electrophoresed
by 12% SDS-PAGE. The sample was then transferred to
PVDF membrane (Millipore) and immunoblotted with
goat anti-human CD3 ζ antibody (Santa Cruz Biotechnol-
ogy). The blot was incubated with horseradish peroxidase-
conjugated rabbit anti-goat IgG (Sigma) and detected by
ECL Western Blotting Analysis System (Alpha Innotech).
Functional analysis of EGFRvIII/CAR+ T cells
Cytotoxicity assay was done as described [15]. Briefly,
1×106 target cells were labeled with 0.1 mCi (3.7 MBq)
51Cr and mixed with decreasing numbers of effector
cells at effector-to-target ratios (E:T) of 40:1, 20:1, 10:1
and 5:1. After 4 h incubation, supernatants were col-
lected and radioactivity was measured in a WIZARD2
gamma counter (Perkin-Elmer). The mean percentage of
specific lysis of triplicate wells was calculated according
to the following formula: (test release - spontaneous re-
lease)/(maximal release - spontaneous release) × 100.
GFP+ T cells and non-transduced (NT) T cells were used
as control of effector cells.
Shen et al. Journal of Hematology & Oncology 2013, 6:33 Page 4 of 7
http://www.jhoonline.org/content/6/1/33Cytokine release assay was performed by a co-culture
of 2×105 T cells with 1×106 target cells in 200 μl me-
dium per well in 96-well-plate triplicately. After 24 h,
supernatants were assayed for IFN-γ production using
ELISA (R&D Systems). The control of effector cells is
the same as above cytotoxicity assay; the control of tar-
get cells is EGFRvIII-negative parental U87 cells.
In vivo antitumor activity of EGFRvIII/CAR+ T cells
Xenograft tumor mouse model was established by sub-
cutaneous (s.c.) flank injections of 5×106 EGFRvIII ex-
pressing U87 cells in 6-week-old female BALB/cA-nude
mice (Chinese Academy of Science Shanghai Experi-
mental Animal Center). When the tumor burden rea-
ched about 500 mm3 in about 10–14 days after tumor
cells inoculation, the mice were assigned to different
groups (5 in each group) and injected with 1×107 differ-
ent T cells/100 μl (EGFRvIII/CAR-transduced T cells,
GFP-transduced T cells, and control PBS) either either
systemically to tail vein or locally to the tumor mass.
Tumor growth was subsequently monitored by caliper
measurement and tumor volume was calculated using
the formula: 1/2 × length × (width)2. The mice were
killed when tumor volume reached >2,000 mm3. This
study was carried out in strict accordance with the re-
commendations in the Guide for the Care and Use of
Laboratory Animals. The protocols were approved by
the Animal Care Committee of Zhengzhou University
(Protocol No. 011–026).
Statistical analysis
ANOVA was used to identify the possible difference
among different treatment groups. Once the difference
is confirmed, Student’s t test was applied to calculate the
significance in the difference between two treatment
groups (P values). P-Values less than 0.05 were consi-
dered statistically significant.
Results
EGFRvIII/CAR was constructed and T cells were modified
successfully by lentiviral EGFRvIII/CAR
To generate EGFRvIII-specific T cells, chimeric EGFRvIII/
CAR was constructed As shown in Figure 1A, EGFRvIII/
CAR encodes a fusion protein consist of IgG κ leader
peptide, EGFRvIII scFv, the hinge and TM region of hu-
man CD8α (amino acids 135–205), intracellular signal do-
main of ICOS (amino acids 165–199) and the CD3ζ chain
(amino acids 52–163). No extra linker or space was used
between gene fragments since it may increase the im-
munogenicity of EGFRvIII/CAR leading to immune de-
struction of the transduced T cells in vivo.
Lentiviral EGFRvIII/CAR was prepared for transduc-
tion of CD3+ T cells. The titers of Lentiviral EGFRvIII/
CAR ranged from 1×106 to 10×106 transducing units/mldetermined by QuickTiter™ Lentivirus Quantitation Kit
(Cell BioLabs). After CD3+ beads selection of human
PBMCs, the purity of CD3+ T cells were almost 100%,
with 39.33% CD8+ T cells and 60.47% CD4+ T cells as
indicated in Figure 1B (middle). The surface expression
of EGFRvIII/CAR on T cells was confirmed by flow cyto-
metric analysis using anti-mouse F(ab)2-FITC. As shown
in Figure 1B (right), EGFRvIII/CAR expression efficiency
reached 73.65% of CD3+ T cells, of which 31.25% were
CD8+ T cells (CTLs). The transduction efficiency was
usually about 70%. The whole population of EGFRvIII/
CAR transduced T cells was treated as EGFRvIII/CAR+
T cells for subsequent experiments.
The EGFRvIII/CAR protein expression was verified by
immunoblotting. Cell lysates of EGFRvIII/CAR trans-
duced and untransduced T cells were separated by SDS-
PAGE under reducing condition and immunoblotted
with goat anti-human CD3ζ antibody. As shown in
Figure 1C, under reducing conditions, endogenous CD3ζ
chain was detected as a 15 kDa band in both transduced
and untransduced T cell lysates. Additional band of ap-
proximate 57 kDa were observed in EGFRvIII/CAR
transduced T cells but absent in untransduced T cells,
consistent with the calculated size of EGFRvIII/CAR
protein.
EGFRvIII/CAR+ T cells demonstrated specific and efficient
cytotoxicity against EGFRvIII expressing glioma cells
A standard 4-hour 51Cr release assay was performed to
determine whether the EGFRvIII/CAR+ T cells could re-
cognize and kill the EGFRvIII expressing U87 cells. A
robust enhancement in the cytotoxicity of the EGFRvIII/
CAR+ T cells against the EGFRvIII expressing glioma
cells was detected as an increase in E:T ratio, A sig-
nificant difference was noticed in the EGFRvIII specific
killing at each E:T ratio (P<0.05, Figure 2A, Left) be-
tween EGFRvIII/CAR+ T cells and control GFP+ or non-
transduced T cells. The killing activity exceeded 60% at
10:1 of E:T ratio. In contrast, no evident killing activity
was found among T cells of three different groups to-
ward control target cells (EGFRvIII-negative U87 cells,
Figure 2A, Right). This result confirmed the specificity
and efficiency of cytotoxic T cell response against
EGFRvIII expressing glioma cells when EGFRvIII/CAR
was grafted onto T cells.
EGFRvIII/CAR+ T cells secreted IFN-γ in an EGFRvIII
dependent mechanism
To determine whether EGFRvIII/CAR+ T cells become
activated and acquire effector cell functions when en-
countering EGFRvIII target, we performed a cytokine re-
lease assay. When co-cultured with EGFRvIII expressing
U87 cells, EGFRvIII/CAR+ T cells released a substantial
amount of IFN-γ, an indicative of T cell activation. In
CAR + T cells
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Figure 2 Functional analysis of EGFRvIII/CAR+ T cells. (A) Cytotoxic activity of EGFRvIII/CAR+ T cells. (Left) Target cells were EGFRvIII-expressing
U87 cells which can be lysed by EGFRvIII/CAR+ T cells, not by GFP+ and NT T cells. (Right) Target cells were EGFRvIII-negative U87 cells, which can
not be lysed by either EGFRvIII/CAR+ or control T cells. (B) Cytokine release of EGFRvIII/CAR+ T cells. Only EGFRvIII/CAR+ T cells released significant
amount of IFN-γ when co-cultured with EGFRvIII-expressing U87 cells. No increased IFN-γ expression was detected when co-cultured with
EGFRvIII-negative U87 cells, nor from control GFP+ and NT T cells. Results are the mean and the SD from experiments in triplicate. * indicate
P<0.05.
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fector cells (GFP+ and non-transduced T cells) or control
target cells (parental U87 cells) groups (P<0.05, Figure 2B).
These results indicate that EGFRvIII/CAR+ T cells can be



























Figure 3 In vivo antitumor activity of EGFRvIII/CAR+ T cells.
EGFRvIII expressing U87 cells were used for xenograft mouse model.
EGFRvIII-bearing BALB/cA-nude mice received different treatments:
group A, EGFRvIII/CAR+ T cells (IT); group B, EGFRvIII/CAR+ T cells (IV);
group C, GFP+ T cells (IV); group D, PBS (IV). Results are expressed as
a mean tumor volume (mm3±SD) with n = 5 for all groups. The
standard deviation (SD) is represented by error bars.dependent manner, which was consistent with previous
findings that the CAR modified T cells expressing a cos-
timulatory signaling domain release increased amount of
cytokines [9].
EGFRvIII/CAR+ T cells inhibited the in vivo growth of
EGFRvIII expressing glioma cells
We developed a xenograft model by inoculating the
EGFRvIII-expressing U87 cells in the flanks of BALB/
cA-nude mice. The tumor-loaded mice received injections
of 1×107 EGFRvIII/CAR+ T cells, GFP+ T cells and PBS,
respectively. Tumor sizes in mice receiving EGFRvIII/
CAR+ T cells started to shrink three weeks after adoptive
cell transfer, while tumors in other two groups continued
to grow. Statistical analysis of the tumor growth curves re-
vealed significant differences between the EGFRvIII/CAR
group and control groups (P<0.05, Figure 3), confir-
ming the potent antitumor property of the inoculated
the EGFRvIII/CAR+ T cells in vivo. We excluded the
possibility that the antitumor effect of the EGFRvIII/
CAR+ T cells resulted from their allogeneic effect be-
cause the inoculated GFP+ T cells did not show any
evident effects on tumor growth. In addition, we were
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had a similar efficacy to that of local intratumor injection.
Discussions
Adoptive transfer of genetically modified T cells shows
some advantages over the mobilization of the endo-
genous T cell repertoire in cancer immunotherapy. The
theoretical advantages and technical feasibility of CAR
facilitate the development of cancer immunotherapy.
The notions that CAR endows T cells antigen specific
recognition, activation and proliferation in an MHC
independent manner have been consolidated by some
pre-clinical studies showing that retargeted T cells can
recognize and kill cancer cells expressing tumor associ-
ated antigen or specific antigen in vitro and in vivo. Cel-
lular immunotherapy adopting such retargeted T cells
has shown significant potential in the treatment of ma-
lignant diseases. The mounting data have provided solid
support for future clinical application of such therapy in
cancers such as leukemia, colorectal colon cancer, and
prostate cancer [17-19].
Recent efforts to improve the antitumor efficacy of
CAR-based therapy are mainly based on the theory of
the two-step T cell activation. Major progress has been
made since the introduction of the costimulatory signal-
ing into architecture of CAR. With the in-depth under-
standing of costimulatory receptors in T cell immune
response, several costimulatory molecules were embed-
ded in the CAR and their roles in coordinating anti-
tumor immunity were explored [20]. The observations
from other groups and our own have thus far established
that the inclusion of costimulatory molecule from B7 re-
ceptor family (CD28 or ICOS) results in an increased
production of of IFN-γ, TNF-γ, and GM-CSF compared
with the CAR with the inclusion of either CD134 or
CD137 of TNFR family. CD28 is more potent than other
costimulatory molecules with respects to enhanced IL-2
production, improved clonal expansion and persistence
of CAR T cells. Finney and colleagues have demon-
strated that ICOS in the CAR induces the maximal ef-
fect on cell lysis [9]. Thus, we hypothesized that the
incorporation of ICOS into CAR favors the antitumor
properties of CAR-armed T cells. Our results support
our hypotheses: CAR-armed T cells demonstrate effi-
cient killing of tumor cells and abundant Th1 cytokine
IFN-γ is released in an EGFRvIII-specific manner. There-
fore, our results are consistent with the previous findings
and consolidate the notion that the presence of ICOS as
an intracellular costimulatory signaling is crucial for en-
hanced T cell response to tumor cells.
The efficacy of CAR can be affected by many factors
including the affinity of the selected scFv, the size of
hinge region, the combination of signaling domain(s),
the type of modified T cell subsets, etc. The majorconcern of CAR T cell transfer is the possible recogni-
tion of the antigen expressed on normal cells by CAR T
cells. Such off-site on-target immune injury causes ad-
verse effects, some of which may be fatal. Therefore, it is
important to carefully select the target antigens that are
specifically expressed in cancer cells, but not in normal
cells. EGFRvIII is a commonly found mutant of EGFR
and exclusively expressed in a wide range of cancers. In
addition to its tumor specific expression, EGFRvIII is
also involved in oncogenic phenotypes and changes the
properties of tumorigenicity. Since its discovery, EGFRvIII
has become an increasingly attractive molecule for cancer
therapy. The EGFRvIII scFv from antibody 3C10 and MR1
was used for CAR construction and the CAR modified
T cells demonstrated EGFRvIII-specific tumor cell lysis
in vitro and in vivo [21,22]. Recently, Rosenberg’s group
analyzed scFv sequences of seven EGFRvIII specific mAbs
and assembled the third generation of chimeric antigen
receptor (139-28BBZ CAR). The T cells transduced with
retroviral EGFRvIII/CAR have been shown an EGFRvIII-
specific cell lytic activity [23]. In this study, lentivirus-
mediated transduction enriched the EGFRvIII/CAR+ T
cells to about 70%. Functionality assay demonstrated that
these redirected T cells exert efficient cytotoxic T cell re-
sponse in an EGFRvIII specific manner and secret cyto-
kine IFN-γ in an antigen dependent way. The EGFRvIII/
CAR engrafted T cells pave a way for antitumor in animal
model as well as in clinical settings.
In our study, we used CD3+ T cells, instead of purified
CD8+ CTLs only, to investigate the performance of CAR
because CD4+ T cells have been shown to augment the
function of CD8+ T cells. The results of our EGFRvIII-
bearing mouse model demonstrates that CD3+ T cells
transduced with EGFRvIII/CAR have significantly higher
antitumor activity than the T cells in control groups,
which supports the theory that adoptive transfer of
mixed populations of antigen-specific CD8+ and CD4+ T
cells promotes overall antitumor immunity. With re-
gards to the administration route of T cells, both intratu-
mor injection and venous injection show similar efficacy.
For clinical purpose, engraftment of adoptively trans-
ferred T cells in host is a major challenge for achieving
therapeutic benefit. Ongoing studies are exploring opti-
mal combinations of costimulatory molecules and T cell
subsets with long-term cytotoxicity [24]. Also, most of
mice in groups of the EGFRvIII/CAR+ T cells and GFP+
T cells suffered from graft versus host diseases (GVHD)
to some extent. The symptoms of GVHD usually started
5 weeks after T cells infusion, including less activity, ruf-
fled fur, skin rash, hunched back and weight loss. The le-
thality due to the transfusion-associated GVHD was rare
and there was no difference between mice treated with
EGFRvIII/CAR+ T cells and GFP+ T cells with regard to
the severity of GVHD.
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Our study demonstrates that the EGFRvIII/CAR-modified
T cells are capable of destroying glioma cells efficiently in
an EGFRvIII specific manner and release IFN-γ in an
antigen dependent manner. The specific recognition and
effective killing activity of the EGFRvIII-directed T cells
with ICOS signaling domain provides a basis for further
studies in clinical application of cancer treatment.
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